CLINICAL PROSTATE CANCER RESEARCH
Our group is concerned with the identification of markers for therapeutic responsiveness, prognostic markers, and new markers of early prostate disease. We take a multidisciplinary approach that utilises expertise from a number of cancer researchers within and outside the Garvan, as well as clinicians and pathologists. Our research aims to identify genes and pathways whose expression changes can predict the development of aggressive life-threatening prostate cancer or resistance to chemotherapy used for the treatment of advanced stage prostate cancer.
Mahon KL, Lin HM, Castillo L, Lee BY, Lee-Ng M, Chatfield MD, Chiam K, Breit SN, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer MJ, Stockler MR, Daly RJ, Henshall SM, Horvath LG. Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. Br J Cancer. 2015: 112 (8):1340-1348
Lee BY, Timpson P, Horvath LG, Daly RJ. FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther. 2015; 146:132-149
Birch SE, Kench JG, Takano E, Chan P, Chan AL, Chiam K, Veillard AS, Stricker P, Haupt S, Haupt Y, Horvath L, Fox SB. Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death. Ann Oncol. 2014; 25(12):2392-2397
Galletti G, Matov A, Beltran H, Fontugne J, Miguel Mosquera J, Cheung C, MacDonald TY, Sung M, O'Toole S, Kench JG, Suk Chae S, Kimovski D, Tagawa ST, Nanus DM, Rubin MA, Horvath LG, Giannakakou P, Rickman DS. ERG induces taxane resistance in castration-resistant prostate cancer. Nat Commun. 2014; 5:5548
Mahon KL, Qu W, Devaney J, Paul C, Castillo L, Wykes RJ, Chatfield MD, Boyer MJ, Stockler MR, Marx G, Gurney H, Mallesara G, Molloy PL, Horvath LG, Clark SJ; PRIMe consortium. Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. Br J Cancer. 2014; 111(9):1802-1809
Lin H-M, Castillo L, Mahon KL, Chiam K, Lee BY, Nguyen Q, Boyer MJ, Stockler MR, Pavlakis N, Marx G, Mallesara G, Gurney H, Clark SJ, Swarbrick A, Daly RJ and Horvath LG (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br J Cancer 110:2462-2471.
Thompson JE, Moses D, Shnier R, Brenner P, Delprado W, Ponsky L, Pulbrook M, Böhm M, Haynes A-M, Hayen A and Stricker PD (2014). Multi-parametric magnetic resonance imaging guiding diagnostic biopsy detects significant prostate cancer, and could reduce unnecessary biopsies and over-detection: a prospective study. J Urol advance online publication 8 Feb 2014.
Lee BY, Hochgrafe F, Lin HM, Castillo L, Wu J, Raftery M, Shreeve SM, Horvath LG and Daly RJ (2014). Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer. Mol Cancer Ther 13: 190-201.
Thompson JE, Egger S, Böhm M, Haynes A-M, Matthews J, Rasiah K and Stricker PD (2014). Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning curve: a prospective single-surgeon study of 1552 consecutive cases. Eur Urol 65:521-531.
Savdie R, Horvath LG, Pe Benito R, Rasiah KK, Haynes A-M, Chatfield M, Stricker PD, Turner JJ, Delprado W, Henshall SM, Sutherland RL and Kench JG (2012). High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy. BJU Int 109: 1794-800.
More Garvan Publications
Staff in the Group
Administrative Director - APCRC-NSW
Biobank/Data Manager Prostate Group
Histopathology & Biospecimen Manager
Visiting PhD student
Clinical Data Manager
Visiting Urology Scientist
Honorary Nuclear Medicine Specialist
Blood Processing Technician
In the News
Enhancing prostate cancer prognosis at the micro level - Aug 07, 2012